Boehringer Ingelheim links with Harvard for unmet medical needs research

Family-controlled German drug major Boehringer Ingelheim has established a translational research collaboration with the presidents and fellows of USA-based Harvard College. The goal of the collaboration is for the scientists of Boehringer Ingelheim to work together with the scientific community of Harvard to advance the company’s knowledge in areas of high unmet medical need.

The focus of the different research projects is to identify and investigate novel signaling pathways and drug targets in oncology, cardiometabolic, fibrotic and infectious diseases.

Under an agreement negotiated between Boehringer Ingelheim and Harvard’s Office of Technology Development, which is responsible for all activities relating to the evaluation, patenting and licensing of new inventions and discoveries made at Harvard University and Harvard Medical School, the collaboration will sponsor a variety of research projects by awarding funds to support proposals selected by a joint research committee comprised of representatives from the Harvard Medical School ICCB-Longwood Screening Facility, various Harvard affiliated institutions and Boehringer Ingelheim. The funding, the amount of which has not been disclosed, will enable the Harvard research community to address several RNAi screening projects using specifically tailored screening systems.